RFK Jr. Reconnects with Anti-Vaccine Movement at Health Conference
Robert F. Kennedy Jr. is set to speak at an anti-vaccine conference, marking his first major public appearance with the group since joining HHS.
September 15, 2026
Finance
Financial news, markets, and business updates
FDA Launches Pilot Program to Accelerate Drug Testing Initiatives
The FDA's new pilot program aims to expedite the initiation of human testing for drugmakers, responding to industry demands for faster processes.
September 15, 2026
GSK Expands Pipeline with $750 Million Deal for Chinese Multiple Myeloma Therapy
GSK has secured global rights to a novel multiple myeloma treatment from China's Chimagen Biosciences, enhancing its pipeline with a $750 million investment.
September 15, 2026
NIH Expands Funding Opportunities for Businesses in Health and Science
Businesses can now apply for NIH funding, broadening access to vital resources for health and science advancements.
September 15, 2026
Vera Therapeutics’ Trutakna Demonstrates Efficacy in Phase 3 Kidney Disease Trial
Trutakna effectively stabilized kidney function and reduced risks in patients with IgA nephropathy, prompting Vera to seek full FDA approval.
September 15, 2026
New Research Confirms Exercise Supports Astronauts' Heart Health During Space Missions
A recent study shows exercise helps maintain heart health in astronauts during long-duration space missions, vital for future Mars expeditions.
September 15, 2026
Investigating the End of America’s Largest Cyclospora Outbreak: Questions Remain
U.S. health officials announce the end of a historic cyclospora outbreak, yet its origin remains uncertain despite extensive investigations.
September 11, 2026
Medicaid Introduces Tiered System to Identify Medical Frailty
Medicaid's new tiered system for assessing medical frailty aims to streamline exemptions for the seriously ill, but raises ongoing concerns.
September 11, 2026
Novartis Faces Investor Pressure Amid Drug Setbacks and Biologic Patent Expirations
Novartis investors heighten scrutiny following drug trial failures and the looming expiration of key biologics patents, impacting market confidence.
September 11, 2026
Persistent Cancer Drug Shortages Disrupt Patient Care Across Treatment Centers
Cancer treatment facilities face ongoing drug shortages, complicating patient care and raising concerns over long-term impacts on treatment efficacy.
September 11, 2026
AI Advances in Cardiology: New Tool for Heart Attack Triage Approved
FDA has approved an advanced AI tool to improve triage for heart attack patients, enhancing care during critical events.
September 11, 2026
Cardiovascular Drug Setbacks Spark Concern in Pharmaceutical Sector
Recent failures of cardiovascular drugs from Novartis and Novo Nordisk may hinder the industry's efforts in Lp(a) treatments.
September 11, 2026
Trump Administration Promises $500 Refund Checks for Select ACA Enrollees Ahead of Midterms
The Trump administration plans to issue $500 refund checks to nearly 1 million ACA enrollees without federal subsidies, targeting key swing states prior to elections.
September 10, 2026
Platinum-Based Chemotherapy in Children Linked to Liver Mutations
A recent study reveals the long-term impact of platinum-based chemotherapy on DNA mutations in children, raising concerns for future cancer risks.
September 10, 2026
FDA Halts Shipments from Shoolin Pharma Over Unsanitary Production Conditions
The FDA has suspended Shoolin Pharma's product shipments to the U.S. due to unsanitary conditions and incomplete testing records found during an inspection.
September 08, 2026
UnitedHealth Group's Political Donations Highlight Their Influence in Healthcare Policy
UnitedHealth's financial support for Rep. Katherine Clark raises questions about its impact on healthcare legislation amid ongoing billing debates.
September 08, 2026
AstraZeneca’s New Breast Cancer Drug Receives FDA Approval
AstraZeneca has gained FDA approval for its latest breast cancer medication, marking a significant milestone in oncology treatment.
September 08, 2026
Novartis and Novo Nordisk Face Setbacks in Recent Clinical Trials
Novartis and Novo Nordisk encounter significant trial failures, raising concerns about their drug development strategies and future pipeline viability.
September 08, 2026
AstraZeneca's Tozorakimab Shows Promise as a New COPD Treatment
AstraZeneca's tozorakimab has significantly reduced COPD flare-ups in late-stage trials, hinting at its potential as a leading treatment option.
September 08, 2026
Inhibrx Achieves Milestone in HPV-Positive Head and Neck Cancer Treatment with OX40 Immunotherapy
Inhibrx reports promising results from its OX40-targeted immunotherapy, especially in HPV-positive head and neck cancer patients, marking a notable industry breakthrough.
September 08, 2026